Financials
Financial year 2025
Gross margin
€ 2.4 million
▲ 26% vs 2024
Profit
Healthy€ 909,969
▼ 8% vs 2024
Debts
High€ 1.4 million
▲ 11% vs 2024
IN2PHARMA from Kampenhout, company number BE0895730662, closed financial year 2025 with a result of € 909,969 after tax. For that financial year IN2PHARMA recorded a gross margin of € 2.4 million and equity of € 69,300. Compared with financial year 2024, the result moved from € 984,888 to € 909,969. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
What happened at IN2PHARMA?
What happened at IN2PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 909,969 (▼ 8% vs 2024). Source: NBB ↗
- Ter Loonst BV became a director. NBB
- New establishment in Gent. KBO
- Patrick Van Dooren became a director. NBB
- Jeremy Dielen became a director. NBB
- Emmanuel Vanderhaegen became a director. NBB
- New establishment in Kampenhout. KBO
- Start of the company according to the CBE. KBO
In short
From € 939,127 profit in 2022 to € 909,969 profit in 2025.
Paid € 325,496 in corporate taxes since 2022.
Best year ever: 2023, with € 1.1 million profit.
On average € 158,900 of value added per employee in 2025.
A new publication or filing at IN2PHARMA? We notify you, reason included.
Follow IN2PHARMANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind IN2PHARMA are Patrick Van Dooren, Ter Loonst BV, Jeremy Dielen and Emmanuel Vanderhaegen. The same people are also behind KDT Consulting, STUDIO PHARMA, PHC Group, Arphius and C&N HOLDING.
Directors
According to the 2025 annual accounts
since 2026
Persoon belast met dagelijks bestuur · represented by Caroline Steensels
Also active at: Arphius, C&N HOLDING, KDT Consulting +1 more
since 2026
since 2026
since 2026
Establishments
Establishment units
Physical locations of this company
Terloonststraat 22
1910 Kampenhout
Kerkstraat 108
9050 Gent
Active since 2 April 2026
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Barracuda
Hosting
CLDIN-NL Your Hosting B.V. part of Your.Online, NL
Domain
Domain
in2pharma.com
Registered
2006-09-08
Registrar
Combell NV
Expires
2027-09-08
Website info
Features
Security
Details
- Company number
- 0895.730.662
- VAT number
- BE 0895.730.662
- Registered office
- Terloonststraat 22, 1910 Kampenhout
- Names & denominations
- IN2PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 January 2008
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- in2pharma.com
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten